Pharmaceuticals, Biotechnology and Life Sciences
Novartis’s acute heart failure (AHF) drug study did not meet its primary endpoint of reduction in cardiovascular death through Day 180 or reduced worsening heart failure through Day five when added to standard therapy
Venn Life Sciences, a Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, has reported profit of €0,5 million for the 2016.
Steep Hill Labs, a cannabis science and technology company has entered a joint venture with iCAN:Israel-Cannabis to leverage Steep Hill’s science, IP, methodology, global collaboration and brand.
St. Jude Children’s Research Hospital scientists in association with other researchers have worked out how a crucial cancer-related protein, a “histone writer” called Ezh2, plays a role in suppressing as well as driving the most aggressive form of the brain tumor medulloblastoma.
In vivo electroporation of intratumoral plasmid IL-12 (ImmunoPulse IL-12) enhances immunogenicity in poorly immunogenic mouse cancer models, said OncoSec Medical in a poster presentation in Canada.
Kaya Holdings got its third Marijuana Retailer license from the Oregon Liquor Control Commission (OLCC), and has opened its third Kaya Shack Retail Marijuana location.
Novartis has reported new data suggesting, for the first time, that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance.
Congressional Republicans recrafted their Obamacare replacement bill on Monday in hopes of satisfying critics as U.S. President Donald Trump prepared to promote his first major legislative initiative on Capitol Hill.
Allergan has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURETM XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.
Bristol-Myers Squibb and CytomX Therapeutics, a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, have expanded their 2014 strategic collaboration to discover novel therapies that will include up to eight additional targets using CytomX’s proprietary Probody platform.